ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) reported weaker-than-expected Q3 results, with quarterly losses widening year-on-year below the consensus and sales slightly below Street expectations. Q3 net loss increased to $26.7 million, or $0.23 per diluted share, from $24.6 million, or $0.21 per diluted share. The consensus, usually less items, was a loss of $0.21 per share. Revenue increased to $44.1 million from $23.6 million in the year-ago period, yet was slightly below the Street consensus estimate of $44.3 million. Separately, the drug developing firm said Thursday it earned a $10 million milestone payment from Biogen Idec for starting several studies on ISIS-BIIB3 Rx, a drug that is being developed to treat neurodegenerative diseases. ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) is trading within a 52-week spread of $22.25-$62.66.Extended Stay America Inc (NYSE:STAY) reported Q3 earnings that declined from a year prior while revenue rose about 8%. Adjusted Paired Share income of $59.9 million, or $0.29 per paired share, down from $0.31 per share a year prior. Extended Stay America Inc (NYSE:STAY) reported total revenues for Q3 2014 increased 7.9% over the comparable period in 2013 to $338.6 million. Adjusted Paired Share Income for Q3 2014 was $59.9 million, or $0.29 per diluted Paired Share. Analyst estimates were not available. For 2014, total revenues are expected to increase 6.8% to 7.3% to approximately $1.210 to $1.216 billion. Adjusted EBITDA is expected to range between $550 to $560 million, representing approximately 6% to 8% growth over 2013.The board of directors of ESH Hospitality, Inc., the company's subsidiary, declared a cash dividend of $0.15 per share for Q3 2014, payable to ESH Hospitality, Inc.'s Class A and Class B common shareholders. The dividend will be payable on December 5, 2014 to shareholders of record as of November 20, 2014.Repros Therapeutics Inc (NASDAQ:RPRX) said late Thursday the FDA did not identify any additional clinical studies that would be required for filing the Androxal NDA. The FDA advised that the company's environmental assessment of Androxal planned for the NDA should be discussed with appropriate FDA personnel prior to NDA submission. The FDA stated that due to their evolving interest in this class of chemicals this would be important to avoid late cycle approval delays, and the company plans to engage in those discussions promptly.Repros Therapeutics Inc (NASDAQ:RPRX) does not anticipate that an additional meeting will be held before submission of its NDA given the detailed guidance received and the subsequent response the company will provide the FDA. It says it is confident that it will be able to address all concerns noted in the meeting and believes the discussions provided constructive guidance for the NDA filing.
Discover Hidden Gems
Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.
